Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of <i>BMPR2</i> Mutation

Abstract

BMPR2 mutation carriers with PAH present approximately 10 years earlier than noncarriers, with a more severe hemodynamic compromise at diagnosis.